Diligence memo · auto-generated · as of July 2, 2026

Adaptilens, Inc.

Adaptilens, Inc. looks fair against its niche peers and is quiet on financing cadence.

SourceRaising on rhythm with a 4.4× step-up on the last round — momentum worth tracking before it's priced in.

Businessfiled

Adaptilens, Inc. operates in Other Health Care, based in CHESTNUT HILL.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Adaptilens, Inc. has raised $8.6M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $7.0M on 2024-04-24.

Most recent recorded round closed around 2024-04-24.

Valuation (modeled)modeled

Provath models Adaptilens, Inc. at approximately $36M (range $9.0M–$81M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.98× the median modeled value of Series A Other Health Care companies in 2022–2024 (196 peers) — value vs value, same stage and era. Within the normal band (98% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 13 months.

Last raise 2.2 yr ago; this sector typically re-raises about every 14 months.

Slightly overdue versus sector cadence.

The last round stepped up 4.4× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 73% of Other Health Care peers (5377 compared).

Modeled value ranks above 62% of those peers.

Closest niche peers: CareHarmony, Inc., Dragonfly Endoscopy Inc., NuvoAir Holdings, Inc., Post Acute Recovery, Inc., Micro Interventional Devices, Inc..

Peoplefiled

7 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.